Featuring new FDA guidance on diversity and inclusion in clinical trials, further calls for COVID-19 vaccine clinical trial transparency, how the UN is promoting open science, discussions on the evolving ecosystem of scientific publishing and two recent analyses of predatory journal watch lists.
Blog
Weekly digest: what’s happening in open science?
Featuring a rundown of the latest results from EU Trials Tracker, how pharma could help make vaccine clinical trials trustworthy again, a survey of researchers’ attitudes towards peer reviewing, the citation advantage of preprints, the next consortium to commit to open science and a reminder of the EMWA virtual events.
Weekly digest: what’s happening in open science?
Featuring the upcoming EMWA Virtual Conference, Open Pharma’s new open access advocacy resource, a joint appeal for open science, reflections on equitable scholarly communications, an example of a journal switching from hybrid to full open access and ideas on how to improve discoverability.
In case you missed it – publishing open access saves lives
To celebrate Open Access Week 2020, Open Pharma teamed up with NetworkPharma and MedComms Networking to host an expert panel discussion on multi-stakeholder perspectives on open access publishing of pharma-sponsored research.
Weekly digest: the Open Access Week 2020 edition!
Featuring a round-up of Open Access Week events, highlights from our expert panel discussion with NetworkPharma, an announcement from Galápagos, an open access explainer video, the community’s input on equitable open access, a roadmap to equity in medical communications, and a new open access agreement from Nature.
Using publication plain language summaries to inform and empower patients, caregivers and non-specialists
Is it not ironic that the scientific community often fails to recognize the public in publications?
Weekly digest: what’s happening in open science?
As the UK and much of Europe face a second wave of COVID-19 and local lockdowns, we at Open Pharma continue to hope that all our readers are staying safe and well. We also know that the deluge of information on the COVID-19 outbreak can be incredibly taxing on our mental health so, throughout this period, we have been including links to several well-being resources at the bottom of each weekly digest and will continue to do so. We at Open Pharma would again like to encourage all our readers to look after themselves and their community, to wear a mask and to continue to follow advice from their country’s government and health organizations.
Weekly digest: what’s happening in open science?
Featuring the latest signatory of Plan S, a think piece outlining the future of scholarly communications as the industry moves towards an open publishing model, the results from a survey on the economic impact of COVID-19 on professional societies, a new policy on price transparency from Gates Open Research and an analysis of figshare metadata on the usage of open research data.
Weekly digest: what’s happening in open science?
Featuring the advent of ‘little’ subscription deals for libraries, a reminder of the upcoming Open Access Week panel discussion, a new upload to our figshare, a new trans-inclusive policy from F1000Research and Wellcome Open Research, further commitments to scientific integrity from vaccine developers, and the best and worst institutions in the USA for clinical trial transparency.
Weekly digest: what’s happening in open science?
Featuring highlights and articles from Peer Review Week 2020, the first instalment of the Friends of the National Library of Medicine’s workshop series, and a podcast discussion from ISMPP on the benefits and challenges of the open science philosophy.